HSA Premarket Submission Checklist 2027: What Singapore Manufacturers Should Prepare

The HSA Premarket Submission Checklist 2027 strengthens filing-readiness checks for Singapore medical device registration, following its introduction by the Health Sciences Authority (HSA) at the September 2026 industry briefing.

For manufacturers preparing a Singapore medical device registration, the significance is less about creating new technical evidence and more about submission discipline. The dossier submitted through SHARE needs to be complete, correctly organised and internally consistent before substantive evaluation. This is particularly relevant to applications planned for 2027, when HSA’s stricter completeness-screening rules take effect.

What the HSA Premarket Submission Checklist 2027 changes

The HSA Premarket Submission Checklist consolidates existing requirements rather than introducing new technical requirements. It applies to Class B, C and D applications through the Full, Abridged and Expedited evaluation routes submitted from 1 October 2026. Immediate Class B and C registration applications and change notifications are outside its submission scope.

HSA’s transition period runs through 31 December 2026. From 1 January 2027, incomplete submissions will be rejected without an input request or refund of application fees, requiring a new, complete application.

HSA updated GN-15 Singapore product-registration guidance to Revision 14 in September 2026. HSA GN-15-R14 also includes Annex 4, combining declarations relating to labelling, adverse events and field safety corrective actions.

For manufacturers, an existing ASEAN CSDT or reference-market dossier should not simply be uploaded as-is. It needs to be checked against the Singapore submission structure and the specific HSA registration route being used. A technically strong dossier can still create avoidable delays when administrative documents, configurations, labels and reference approvals do not align.

Where problems are most likely to arise

In practice, completeness problems often appear where documents prepared by different teams need to match.

The List of Configurations should correspond with the models and accessories covered by the application. Product names and intended use should remain consistent across the application, labelling and supporting approvals. Where a submission relies on an overseas reference approval, the device being registered in Singapore should be clearly supported by that approval.

Software medical devices require the same attention. The software version intended for supply in Singapore should be identifiable and consistent with the supporting technical documentation.

The objective is straightforward: HSA should be able to follow the product from the application form through to the technical evidence without having to resolve preventable inconsistencies.

What manufacturers should review before filing

A useful final review for Singapore medical device registration should start with current HSA templates rather than older internal copies. Review GN-15-R14 and its annexes alongside the current GN-17 or GN-18 dossier guidance and electronic-submission instructions. HSA’s guidance page now lists October 2026 revisions to these dossier documents.

The dossier should then be reviewed as one complete submission rather than as separate document folders. Check that the device scope is consistent, that all applicable configurations are accounted for, that reference approvals support the Singapore product, and that the labels and IFU correspond with the configuration intended for the local market.

Technical documentation should be placed under the appropriate SHARE sections. Documents prepared for Europe, the United States or another ASEAN market may provide much of the required evidence, but their original folder structure does not necessarily match HSA’s filing structure.

This is an organisational exercise as much as a technical one.

Why this matters for market-entry planning

Singapore is frequently included early in an ASEAN regulatory strategy. A preventable filing issue can therefore affect more than the immediate HSA application.

It can delay the planned Singapore launch and may affect the sequencing of registrations in other markets where an HSA approval could support an applicable reliance or reference-market pathway.

The better approach is to identify submission gaps before filing. For manufacturers managing registrations across several ASEAN countries, this also creates an opportunity to structure the core dossier for medical device registration across ASEAN so that technical evidence can be reused while country-specific administrative requirements remain properly localised.

Preparing a Singapore submission for 2027

Planning for the HSA submission checklist in 2027 means incorporating a formal completeness review into the registration process, particularly where a dossier has been adapted from another market or assembled across multiple internal teams.

MediPass supports overseas manufacturers with device classification, registration-route assessment, dossier review and HSA medical device registration submission support. Learn more about our Singapore Medical Device Registration services.